Sofiva GenomicsLtd Balance Sheet Health
Financial Health criteria checks 6/6
Sofiva GenomicsLtd has a total shareholder equity of NT$648.7M and total debt of NT$0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are NT$776.5M and NT$127.8M respectively.
Key information
0%
Debt to equity ratio
NT$0
Debt
| Interest coverage ratio | n/a |
| Cash | NT$136.18m |
| Equity | NT$648.66m |
| Total liabilities | NT$127.83m |
| Total assets | NT$776.49m |
Recent financial health updates
No updates
Recent updates
Some Investors May Be Worried About Sofiva GenomicsLtd's (GTSM:6615) Returns On Capital
Apr 14
Estimating The Fair Value Of Sofiva Genomics Co.,Ltd. (GTSM:6615)
Mar 18Sofiva Genomics Co.,Ltd. (GTSM:6615) Investors Should Think About This Before Buying It For Its Dividend
Feb 24Should Weakness in Sofiva Genomics Co.,Ltd.'s (GTSM:6615) Stock Be Seen As A Sign That Market Will Correct The Share Price Given Decent Financials?
Jan 27Our Take On The Returns On Capital At Sofiva GenomicsLtd (GTSM:6615)
Jan 07
A Look At The Intrinsic Value Of Sofiva Genomics Co.,Ltd. (GTSM:6615)
Dec 15Read This Before Buying Sofiva Genomics Co.,Ltd. (GTSM:6615) For Its Dividend
Nov 24Financial Position Analysis
Short Term Liabilities: 6615's short term assets (NT$276.0M) exceed its short term liabilities (NT$83.3M).
Long Term Liabilities: 6615's short term assets (NT$276.0M) exceed its long term liabilities (NT$44.5M).
Debt to Equity History and Analysis
Debt Level: 6615 is debt free.
Reducing Debt: 6615 had no debt 5 years ago.
Debt Coverage: 6615 has no debt, therefore it does not need to be covered by operating cash flow.
Interest Coverage: 6615 has no debt, therefore coverage of interest payments is not a concern.
Balance Sheet
Discover healthy companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/02/04 08:01 |
| End of Day Share Price | 2025/02/04 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Sofiva Genomics Co.,Ltd. is covered by 2 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Yenya Kuo | Capital Securities Corporation |
| Xiaowei Huang | Masterlink Securities Corp. |